Daiichi Sankyo is the global leader in antibody-drug conjugates (ADCs) with Enhertu (HER2) as the flagship asset alongside AstraZeneca, plus datopotamab deruxtecan (Dato-DXd) and patritumab deruxtecan (HER3-DXd) advancing across multiple oncology indications. The ADC platform represents a new standard of care across breast, lung, and gastric cancers. Japan-listed but globally relevant pipeline drives multiple expansion. Yen translation amplifies USD revenue growth.
Signals scoped to JP · Company-specific tagging coming soon.